A Study of Combination Bicalutamide and Raloxifene for Patients With Castration-Resistant Prostate Cancer

Thai H. Ho, Rafael Nunez-Nateras, Yue Xian Hou, Alan H. Bryce, Donald W. Northfelt, Amylou C. Dueck, Bryan Wong, Melissa L. Stanton, Richard W. Joseph, Erik P. Castle

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


A study to evaluate the toxicity of combination bicalutamide and raloxifene was conducted in patients with prostate cancer. No grade 3 or 4 adverse events occurred, and no dose reductions were required. The patient assessment of quality of life showed no statistically significant changes. The combination of bicalutamide and raloxifene treatment was well tolerated. Background Prostate tissue expresses 2 estrogen receptor (ER) isoforms, ER-α and ER-β, and estrogen-based therapies have shown activity in preclinical studies. Raloxifene, a selective ER modulator, has inhibited the growth of prostate cancer xenograft models and was tested in a phase II trial of castration-resistant prostate cancer (CRPC), with some patients achieving stable disease. However, no studies have examined the safety of the combination of bicalutamide plus raloxifene for CRPC. Therefore, we investigated the safety of treatment with bicalutamide plus raloxifene in patients with CRPC in an initial study. Materials and Methods We conducted a study to evaluate the toxicity (primary endpoint) of the combination of bicalutamide (50 mg) and raloxifene (60 mg) in 28-day cycles (maximum, 6 cycles) in men with progressive CRPC. The secondary endpoint, quality of life (QOL), was assessed by patients using a 6-item linear analog self-assessment or hormonal domain scale of the Expanded Prostate Cancer Index Composite. Results We enrolled 18 patients with CRPC in the study to evaluate the safety of, and patient assessment of QOL (mental, physical, social, emotional, and spiritual) with, bicalutamide plus raloxifene therapy. No grade 3 or 4 adverse events occurred. None of the 18 patients required dose reductions. The patient assessment of QOL showed no statistically significant changes after 2 treatment cycles. The median progression-free survival with bicalutamide plus raloxifene was 1.9 months (95% confidence interval, 1.8-2.8 months). Conclusion The results of the present study have shown that bicalutamide/raloxifene treatment is well tolerated. However, limited clinical activity occurred in men with CRPC who had previously undergone secondary hormonal therapy or chemotherapy.

Original languageEnglish (US)
Pages (from-to)196-202.e1
JournalClinical Genitourinary Cancer
Issue number2
StatePublished - Apr 1 2017


  • Androgen receptor
  • Bicalutamide
  • Castration resistant prostate cancer
  • Estrogen receptor
  • Prostate
  • Raloxifene

ASJC Scopus subject areas

  • Oncology
  • Urology


Dive into the research topics of 'A Study of Combination Bicalutamide and Raloxifene for Patients With Castration-Resistant Prostate Cancer'. Together they form a unique fingerprint.

Cite this